IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.

Maloum, Karim; Settegrana, Catherine; Chapiro, Elise; Cazin, Bruno; Leprêtre, Stéphane; Delmer, Alain; Leporrier, Michel; Dreyfus, Brigitte; Tournilhac, Olivier; Mahe, Beatrice; Nguyen-Khac, Florence; Lesty, Claude; Davi, Frederic; Merle-Béral, Hélène

Maloum, Karim; Settegrana, Catherine; Chapiro, Elise; Cazin, Bruno; Leprêtre, Stéphane; Delmer, Alain; Leporrier, Michel; Dreyfus, Brigitte; Tournilhac, Olivier; Mahe, Beatrice; Nguyen-Khac, Florence; Lesty, Claude; Davi, Frederic; Merle-Béral, Hélène.

Affiliation

Maloum K; Service d'Hématologie Biologique, CHU Pitié-Salpêtrière, Paris, France. karim.maloum@psl.aphp.fr

Ann Hematol ; 88(12): 1215-21, 2009 Dec.

Article in En | MEDLINE | ID: mdl-19340428

Subject(s)

ADAM Proteins/genetics; Antineoplastic Agents/therapeutic use; Cyclophosphamide/therapeutic use; Genes, Immunoglobulin Heavy Chain/genetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase/genetics; Vidarabine/analogs & derivatives; Biomarkers, Tumor/genetics; DNA Mutational Analysis; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/genetics; Mutation; Remission Induction; Treatment Outcome; Vidarabine/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / Cyclophosphamide / ADAM Proteins / Genes, Immunoglobulin Heavy Chain / Lipoprotein Lipase / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2009 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google